Please assess the completion status of the following clinical trial:

Trial Title: Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Participants must be adults aged ≥18 years, at the time of signing the informed consent.~2. Participants should have CKD defined by having an estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m2 (calculated using CKD-EPI equation) measured twice at least 90 days apart. (The eGFR should be measured when the participant is considered to be in a steady state without recent changes in volume status, medications that could impact the result (eg, nonsteroidal anti-inflammatory drugs, aminoglycosides, co-trimoxazole), or changes in dietary protein intake.)~3. Prevalent HK with serum K+ \>5 mmol/L.~4. Male and/or female~5. Capable of giving signed informed consent as described in Appendix A which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Informed consent must be obtained prior to any study-specific procedures performed.~Exclusion Criteria:~1. Screening serum K+ value which, in the opinion of the investigator, requires immediate medical intervention (ie, cannot wait until after tasting procedures).~2. As judged by the investigator, any evidence of any condition which in the investigator's opinion makes it undesirable for the participant to participate in the study.~3. Known history of drug or alcohol abuse within 6 months of screening.~4. History of QT prolongation associated with other medications that required discontinuation of that medication, including congenital long QT syndrome.~5. Symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Participants with atrial fibrillation controlled by medication are permitted.~6. Have a life expectancy of \<6 months.~7. 12-lead ECG with reported QTcF \>550 msec at screening.~8. Are current smoker.~9. Have mouth ulcers/mouth infection, respiratory infection, nasal congestion, or other condition, medication, or procedure which may interfere with sense of smell or taste, in opinion of the investigator.~10. Participants currently prescribed a K+ binder at time of screening/enrolment.~11. Participants unable to hold other oral medications from 3 hours prior to the start of tasting through 3 hours after the end of tasting.~12. Current participation or participation within the previous 28 days in another clinical study with an investigational product administered.~13. Participants with a known hypersensitivity to Lokelma, Veltassa, or S/CPS or any of the excipients of the NIMPs.~14. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).~15. Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements.~16. Previous enrolment or randomisation in the present study.~17. For women only - currently pregnant (confirmed with positive pregnancy test) or breast-feeding.~18. Participants unable to read the local language and therefore unable to complete the questionnaires.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- dialysis-dependent (Type: None): chronic kidney disease patients with hyperkalaemia and dialysis-dependent
- non-dialysis-dependent (Type: None): chronic kidney disease patients with hyperkalaemia and non-dialysis-dependent

Based on this trial design, predict the completion outcome and termination type (if applicable).